Newsfeeds Archive - Spark Newswire

2 minute read

Inventiva Cash And Cash Equivalents Amounted To €11.0 Million As Of March 31, 2024

May 21, 4:03 PM

Key Financial ResultsCash, cash equivalents and depositsAs of March 31, 2024, the Company's cash and cash equivalents amounted to €11.0 million, short-term deposits to 0.1 million, and long-term deposit to €19.0

IVA

1 minute read

Inventiva Receives Recommendation From The 4th Scheduled Data Monitoring Committee Meeting Of The NATiV3 Phase III Clinical Trial With Lanifibranor In Patients With MASH/NASH

By Benzinga Newsdesk

May 16, 4:02 PM

The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on the unblinded review

IVA

2 minute read

Why Is Inventiva’s Stock Trading Higher on Monday?

By Vandana Singh

May 13, 2:08 PM

Inventiva's Lanifibranor improves cardiometabolic health in MASH/NASH patients. It lowers fasting glucose, reduces cardiovascular risk, and increases adiponectin levels. Weight gain correlates with health improvement.

IVA

1 minute read

News

Inventiva Announces the Publication in Nature Communications of Additional Results from NATIVE Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

By Benzinga Newsdesk

May 13, 3:12 AM

Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"),

IVA

5 minute read

Inventiva FY23 €(2.43) Vs €(1.31) YoY; Revenues For 2023 Amounted To €17.5 Million, Up By 43.4%, Compared To €12.2 Million In 2022

By Benzinga Newsdesk

March 27, 4:03 PM

Key financial results for the full year of 2023As of December 31, 2023, the Company's cash and cash equivalents amounted to €26.9 million, short-term deposits to €0.01 million, and long-term deposit to €9.0 million,

IVA

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

February 19, 1:30 PM

Gainers Applied Therapeutics (NASDAQ:APLT) stock rose 42.5% to $5.34 during Monday’s regular session. The market value of their…

AMN

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s Pre-Market Session

By Benzinga Insights

February 19, 9:05 AM

Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 30.3% to $4.95 during Monday’s pre-market session. The market value of their…

AMIX

4 minute read

Why DoorDash Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Friday’s Mid-Day Session

By Avi Kapoor

February 16, 2:04 PM

Shares of DoorDash, Inc. (NASDAQ: DASH) fell sharply in today’s session as the company reported mixed financial results for its fourth quarter.

AMAT

2 minute read

Movers

12 Health Care Stocks Moving In Friday’s Intraday Session

By Benzinga Insights

February 16, 1:31 PM

Gainers OneMedNet (NASDAQ:ONMD) shares rose 91.2% to $1.44 during Friday’s regular session. The market value of their outstanding…

AMN

2 minute read

Why Is Liver Disease-Focused Inventiva Stock Trading Lower Today?

By Vandana Singh

February 16, 12:30 PM

Inventiva announces a voluntary pause in NATiV3 Phase 3 trial of lanifibranor for NASH due to a treatment-related SUSAR. Screening and randomization halted temporarily.

IVA